Yes, Breztri Must Be Taken Every Day as Scheduled Maintenance Therapy
Breztri is a daily maintenance medication that must be taken twice daily, every day, regardless of whether you have symptoms—it is not a rescue inhaler and will not provide immediate relief during acute breathing problems. 1
Dosing Schedule
The FDA-approved dosing for Breztri is 2 inhalations twice daily (morning and evening) by oral inhalation 1. This scheduled dosing must be maintained consistently because:
- It is designed for maintenance treatment only, not for acute symptom relief 1
- The three components (budesonide/glycopyrrolate/formoterol) work together to prevent COPD exacerbations and reduce mortality risk over time
- Missing doses compromises the therapeutic benefits that accumulate with regular use
Why Daily Use Is Critical
The 2023 Canadian Thoracic Society guidelines strongly recommend triple therapy (LAMA/LABA/ICS combinations like Breztri) for patients with moderate-to-severe COPD who are at high risk of exacerbations (≥2 moderate exacerbations or ≥1 severe exacerbation requiring hospitalization in the past year) 2. The evidence shows:
- Significant mortality reduction compared to dual therapy (LAMA/LABA alone)—with hazard ratios of 0.54-0.64 in major trials 2
- Reduced exacerbation rates by 24% compared to dual bronchodilator therapy 2
- Improved lung function, dyspnea, and health status that require consistent daily dosing to maintain 2
Common Pitfall to Avoid
Do not use Breztri as a rescue medication. Patients must also have a separate short-acting bronchodilator (like albuterol) for acute symptom relief 2. Breztri takes time to build therapeutic effect and will not work quickly enough during sudden breathing difficulties.
When to Rinse Your Mouth
After each inhalation, rinse your mouth with water without swallowing to reduce the risk of oral candidiasis (thrush) from the inhaled corticosteroid component 1. This is a simple but important step to prevent a common side effect.
Do Not Stop Without Medical Guidance
The guidelines specifically recommend against stepping down from triple therapy in patients at high risk of exacerbations, as withdrawing the inhaled corticosteroid component can lead to worsening lung function, decreased health status, and increased exacerbation risk—particularly in patients with blood eosinophil counts ≥300 cells/µL 2.